elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Lab
API & MCP
Pricing
Log in
Sign up
Home
/
Subjects
/
Sorafenib
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Sorafenib
RIS
0.003
(Research Intensity Score)
Papers
312
Top papers
Thyroid Cancer
2024 · 638 citations
Thyroid Cancer: Epidemiology, Classification, Risk Factors, Diagnostic and Prognostic Markers, and Current Treatment Strategies
2025 · 108 citations
Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer
2023 · 280 citations
The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects
2020 · 1156 citations
Targeted therapy for hepatocellular carcinoma
2020 · 785 citations
Newest papers
Thyroid Cancer: Epidemiology, Classification, Risk Factors, Diagnostic and Prognostic Markers, and Current Treatment Strategies
2025 · 108 citations
D-lactate and glycerol as potential biomarkers of sorafenib activity in hepatocellular carcinoma
2025 · 17 citations
The Potential Therapeutic Role of Beta-Caryophyllene as a Chemosensitizer and an Inhibitor of Angiogenesis in Cancer
2025 · 18 citations
AGPAT4 targeted covalent inhibitor potentiates targeted therapy to overcome cancer cell plasticity in hepatocellular carcinoma mouse models
2025 · 13 citations
Unveiling the potency of ZnO and CuO nanocomposites in combating hepatocellular carcinoma by inducing cell death and suppressing migration
2025 · 14 citations
A sample from the 100 top papers behind Sorafenib.
Create a free account to browse them all →
Sorafenib's history
Research intensity over time
Explore Sorafenib's full history
Hover any year for its value and switch resolutions with a free account. Personal adds monthly detail and the historical-intensity (HRI) line.
Create a free account
Already have an account?
Log in
to explore the data.
Close ✕
Sorafenib's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link